CagriSema confers ‘high magnitude’ of HbA1c, weight reductions in type 2 diabetes

morningstar.com·Jun 7, 2026 · 1 mese fa

Novo Nordisk's CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026

morningstar.com·Jun 6, 2026 · 1 mese fa

People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data

benzinga.com·Jun 8, 2026 · 1 mese fa

Novo Nordisk Highlights Positive Weight-Loss Data Across Multiple Programs - Novo Nordisk (NYSE:NVO)

morningstar.com·Jun 12, 2026 · 1 mese fa

In HelloNation, Medical Weight Loss Expert Patty Schultz Explains Semaglutide and Tirzepatide

adnkronos.com·Jun 4, 2026 · 1 mese fa

ERA Congress: Semaglutide linked to better quality of life in diabetes and kidney disease, FLOW trial shows

morningstar.com·Jun 7, 2026 · 1 mese fa

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

morningstar.com·Jun 6, 2026 · 1 mese fa

Novo Nordisk's investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes—presented at ADA 2026

economictimes.indiatimes.com·Jun 3, 2026 · 1 mese fa

Zydus Semaglutide approval: Delhi HC directs CDSCO to decide on patient safety concerns